Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$5.39
-0.11 (-2.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $10.4M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
N/A
•EV/EBITDA
23356.2x
↑ROE
-3.7%
↓Gross Margin
41.5%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.9%
FCF CAGR
—
FCF margin
-9.6%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $343.4M · net income $-37.3M · FCF $-33.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $343.4M | $343.4M | $270.3M | $213.9M | $160.2M |
| Net Income | $-37.3M | $-37.3M | $-198.8M | $-267.9M | $-287.5M |
| EBITDA | $116040.50 | $116040.50 | $-170.7M | $-231.8M | $-253.7M |
| EPS | -0.07 | -0.07 | -0.34 | -0.46 | -0.49 |
| Gross Margin | 41.5% | 41.5% | 27.2% | 61.2% | 46.1% |
| Operating Margin | 0.3% | 0.3% | -51.2% | -50.4% | -80.0% |
| Net Margin | -10.9% | -10.9% | -73.5% | -125.2% | -179.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Current Ratio | 12.39 | 12.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-33.0M | $-33.0M | $76.0M | $10.4M | $-32.6M |
| Returns | |||||
| ROE | -3.7% | -3.7% | -19.2% | -21.2% | -18.8% |
| Valuation | |||||
| EV/EBITDA | 23356.17 | 23356.17 | — | — | — |
| P/B | 2.89 | 2.89 | 2.06 | 3.52 | 4.30 |
| Growth & Yield | |||||
| Revenue Growth | 27.1% | 27.1% | 26.4% | 33.5% | — |
| EPS Growth | 79.4% | 79.4% | 26.1% | 6.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+41.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.34 → -0.07
Residual
+41.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.